

Amy Schulman
Managing Partner
LS Polaris Innovation Fund and Polaris Partners

Amy is a healthcare investor and managing partner at Polaris Partners and LSPIF. Amy joined Polaris in 2014, bringing her commercial expertise to the startup biotech community. She currently represents Polaris investments on boards and as executive chair of SQZ Biotech, and as the active CEO and co-founder of Lyndra. She is also a director of publicly traded Alnylam Pharmaceuticals and Cycleron Pharmaceuticals. Schulman is also on the faculty of the Harvard Business School.

Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and was instrumental in its sale to Nestle for \$11.85 billion in 2012. Soon after, Schulman became the president of Pfizer Consumer Healthcare.

Schulman has received numerous awards including Xconomy's 2017 Newcomer Award, Scientific American's 2015 Worldview 100 List, Fierce Biotech's 2014 Top 15 Women in Biotech, and Fortune Magazine's 2013 50 Most Powerful Women in Business.

She is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School.